Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 3/20 | 0.48 |
| ▸ | CES2 | O00748 | 3/20 | 0.44 |
| ▸ | CES1 | P23141 | 3/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2768530 | 1.00 | TBXAS1 (0.48) | TBXAS1CES2CES1PTGS2NAAA | |
| SCHEMBL2768526 | 1.00 | TBXAS1 (0.48) | TBXAS1CES2CES1PTGS2NAAA | |
| SCHEMBL16167351 | 0.98 | TBXAS1 (0.47) | TBXAS1CES2CES1PTGS2NAAA | |
| SCHEMBL16167375 | 0.98 | TBXAS1 (0.47) | TBXAS1CES2CES1PTGS2NAAA | |
| SCHEMBL16167353 | 0.98 | TBXAS1 (0.47) | TBXAS1CES2CES1PTGS2NAAA | |
| SCHEMBL16167155 | 0.98 | TBXAS1 (0.47) | TBXAS1CES2CES1PTGS2NAAA | |
| SCHEMBL16167208 | 0.98 | TBXAS1 (0.47) | TBXAS1CES2CES1PTGS2NAAA | |
| SCHEMBL16167372 | 0.98 | TBXAS1 (0.47) | TBXAS1CES2CES1PTGS2NAAA | |
| SCHEMBL16167384 | 0.98 | TBXAS1 (0.47) | TBXAS1CES2CES1PTGS2NAAA | |
| SCHEMBL16167083 | 0.98 | TBXAS1 (0.47) | TBXAS1CES2CES1PTGS2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824952-B1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2010-04-28 | — | — | EP | claimed |
| CN-114051497-B | Chromene compounds and photochromic optical articles | 株式会社德山 | 2024-06-28 | — | — | CN | disclosed |
| CN-113543753-B | Method for absorbing or discharging moisture in ophthalmic medical device and ophthalmic medical device | 国立大学法人东北大学 | 2024-04-19 | — | — | CN | disclosed |
| EP-2984055-B1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | MATERIA INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-9758445-B2 | Preparation of surfactants via cross-metathesis | MATERIA, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9663459-B2 | Preparation of surfactants via cross-metathesis | MATERIA, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160186094-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | MATERIA, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160145204-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | MATERIA, INC. | 2016-05-26 | — | — | US | disclosed |
| EP-2984055-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | Materia, Inc. (US) | 2016-02-17 | — | — | EP | disclosed |
| US-9238715-B2 | Polymerizable composition for ophthalmic and medical use and antimicrobial composition obtained by polymerizing the polymerizable composition | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2016-01-19 | — | — | US | disclosed |
| WO-2015126462-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | MATERIA, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| WO-2014169080-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | MATERIA, INC. (US) | 2014-10-16 | — | — | WO | disclosed |
| US-20140163133-A1 | POLYMERIZABLE COMPOSITION FOR OPHTHALMIC AND MEDICAL USE AND ANTIMICROBIAL COMPOSITION OBTAINED BY POLYMERIZING THE POLYMERIZABLE COMPOSITION | MENICON CO., LTD (JP) | 2014-06-12 | — | — | US | disclosed |
| EP-2578244-A1 | POLYMERIZABLE COMPOSITION FOR OPHTHALMIC AND MEDICAL USE AND ANTIBACTERIAL COMPOSITION OBTAINED BY POLYMERIZING SAME | Nanyang Technological University (SG) | 2013-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160186094-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | SMURF2, EPHX2, SMURF1 | TBXAS1 335/4885CES2 249/4885CES1 437/4885 |
| US-20160145204-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | SMURF2, SMURF1, ABCB4 | TBXAS1 252/4885CES2 378/4885CES1 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.